NAD+ Boosting: The Cellular Energy Revolution for Healthy Aging

There is a molecule inside every cell in your body that you have almost certainly never thought about, and without it you would not survive more than a few minutes. It is called nicotinamide adenine dinucleotide, or NAD+. It does not get the attention that collagen, protein, or vitamin D get. But over the last decade it has become one of the most closely studied molecules in aging biology, and for good reason. Your NAD+ levels are not fixed. They fall as you get older, and researchers now believe that decline plays a real part in how aging feels from the inside.

This article walks through what NAD+ actually does, why it drops, what "NAD+ boosting" really means, and what the human research says so far.

What NAD+ Actually Does

NAD+ is a coenzyme, which is a fancy way of saying it is a helper molecule that other enzymes cannot function without. It shows up in two very different jobs.

The first job is energy. Every time your cells break down food into usable fuel, NAD+ is the shuttle that carries electrons through glycolysis, the citric acid cycle, and finally the electron transport chain inside your mitochondria, where ATP gets made. ATP is the actual currency your cells spend to contract a muscle, fire a neuron, or repair a membrane. No NAD+, no ATP. It is that direct.

The second job is signaling and repair, and this is where the aging connection lives. NAD+ is consumed as a substrate by three families of enzymes. Sirtuins, a group of seven proteins often described as longevity regulators, use NAD+ to switch genes on and off in response to your metabolic state. PARPs, or poly ADP-ribose polymerases, use NAD+ to detect and patch damaged DNA. CD38, an enzyme found on immune cells, also consumes NAD+ as part of inflammatory signaling.

That second set of jobs creates a quiet competition. Sirtuins, PARPs, and CD38 all draw from the same limited NAD+ pool. When DNA damage is high or inflammation is elevated, PARPs and CD38 pull hard on that pool, and there is less NAD+ left over for the sirtuins that regulate mitochondrial function and metabolic health.

Why NAD+ Falls With Age

Measured tissue levels of NAD+ decline with age in skin, liver, muscle, brain, and blood. Researchers describe this as one of the more consistent biochemical signatures of getting older, and the decline appears to be driven from both directions at once.

On the supply side, an enzyme called NAMPT slows down. NAMPT is the rate limiting step in the salvage pathway, the recycling route your body uses to rebuild NAD+ from nicotinamide. When NAMPT activity falls, the recycling line slows, and the whole pool shrinks.

On the demand side, consumption goes up. Accumulated DNA damage keeps PARPs busy, and CD38 expression rises with age as low grade inflammation increases. Work published in Cell Metabolism identified CD38 in particular as a major driver of age related NAD+ decline and the mitochondrial dysfunction that follows.

Slower production, faster consumption. The gap widens over decades, which is part of why the effects are subtle in your thirties and much more noticeable later.

What "NAD+ Boosting" Actually Means

You cannot take NAD+ as a pill and expect it to arrive intact. The molecule is large and charged, and it does not cross cell membranes efficiently. So the field has focused instead on precursors, which are smaller upstream compounds your body converts into NAD+ through pathways it already runs.

The main options look like this.

Nicotinamide mononucleotide, or NMN, sits one enzymatic step away from NAD+. It is the immediate precursor, the product of the NAMPT step that slows down with age, which is a large part of why it has drawn so much research interest.

Nicotinamide riboside, or NR, sits one step further upstream. It is converted to NMN first, then to NAD+.

NMNH is a reduced form of NMN carrying extra hydrogen, and early research suggests it may raise NAD+ more rapidly than the standard forms.

Niacin and nicotinamide, the classic B3 vitamins, also feed the pathway, though they run through different routes and have their own dosing considerations.

The logic behind all of them is the same. Give the salvage pathway more raw material and it can rebuild more NAD+, even when NAMPT activity has slowed.

What the Human Research Shows So Far

Animal work has been striking. A landmark twelve month study in mice found that long term NMN administration reduced age-associated weight gain, improved insulin sensitivity, enhanced energy metabolism, and improved eye function, with no observed toxicity.

Human research is younger and more measured, but it is real and it is accumulating.

The most cited human trial came out of Washington University in 2021. Researchers ran a ten week randomized, placebo controlled, double blind study in postmenopausal women with prediabetes who were overweight or obese. At 250mg per day, NMN increased insulin stimulated glucose disposal measured by hyperinsulinemic euglycemic clamp, the gold standard method, and increased insulin signaling in skeletal muscle. Placebo did not.

A 2023 dose ranging trial in 80 healthy middle aged adults tested 300mg, 600mg, and 900mg of NMN daily against placebo over 60 days. Blood NAD concentrations rose in every NMN group compared to placebo, and the study reported good tolerability across doses.

A separate 2023 randomized, double blind, placebo controlled trial gave 36 healthy middle aged adults 125mg twice daily for twelve weeks. NAD+ metabolism markers rose, the supplement was well tolerated with no adverse events, and arterial stiffness measured by pulse wave velocity trended downward, though that particular result did not reach statistical significance.

In athletes, a six week randomized, double blind trial in 48 amateur runners tested 300mg, 600mg, and 1200mg daily alongside training and found improvements in aerobic capacity.

A 2024 systematic review pulled together ten randomized controlled trials covering 437 participants across doses from 150mg to 1200mg daily and found a consistent safety profile alongside signals in physical performance.

Here is the honest summary. The evidence that oral NMN raises NAD+ in humans and is well tolerated is now reasonably strong. The evidence for specific downstream outcomes, meaning what that extra NAD+ does for energy, metabolism, and how you actually feel, is promising but still early. Sample sizes are small, most trials run twelve weeks or less, and nobody has run the multi year study that would settle the healthy aging question. Anyone telling you otherwise is selling something.

The Absorption Problem Nobody Talks About

There is a practical issue that sits underneath all of this. NMN is a fragile molecule. Stomach acid and digestive enzymes degrade a meaningful share of it before it ever reaches your bloodstream, which means the number printed on the label and the amount that reaches your cells are two different numbers.

This is where delivery technology matters more than dose escalation. Liposomal encapsulation wraps each molecule in a phospholipid layer, a structure made of the same material as your own cell membranes. That layer acts as a shield through the digestive tract and supports more efficient cellular uptake at the other end.

It is worth understanding why this matters commercially, because it explains a lot of the confusion in this category. It is far cheaper to print 1000mg on a label than it is to build a protected delivery system around 250mg. A large unprotected dose can easily deliver less usable NMN than a smaller protected one. Dose on the label is not the same as dose in the cell.

What Else Supports Your NAD+ Levels

Supplementation is one lever, not the only one. The research on NAD+ biology points to several habits that support the same pathways.

Exercise, particularly higher intensity work and resistance training, increases NAMPT expression and improves mitochondrial function. Periods without eating, whether that is a longer overnight fast or simply not grazing all evening, shift cells toward the metabolic state where sirtuin activity rises. Sleep matters because NAD+ levels follow a circadian rhythm and disrupted sleep flattens it. Limiting alcohol helps because ethanol metabolism consumes NAD+ directly. And sun protection matters more than people expect, since UV damage drives PARP activity in skin, which draws down the local NAD+ pool.

None of these are exciting. All of them are free.

Setting Realistic Expectations

NAD+ support is not a stimulant. If you are expecting the sharp lift of a strong coffee, you will be disappointed, and you should be suspicious of any product that promises it.

What people more commonly describe, and what the mechanism would predict, is subtler. Afternoons that do not collapse. Recovery from hard days that takes less time than it used to. A baseline that feels a bit more stable. These are cumulative effects that build over weeks of consistent use, not a switch that flips on day three.

Give any NAD+ precursor at least eight to twelve weeks of daily, consistent use before drawing conclusions. That is the timeframe the human trials used, and it is a fair one to hold yourself to.

About GenuinePurity® Liposomal NMN

GenuinePurity^® Liposomal NMN was built around the two problems this article describes. The first is purity, because this category has a real counterfeit problem and a number of products on the market contain far less NMN than their labels claim. Every batch of GenuinePurity^® Liposomal NMN uses 96% pure beta-nicotinamide mononucleotide, and the Certificate of Analysis is published openly on genuinepurity.com so you can verify what is actually in the bottle rather than take a marketing claim on faith.

The second problem is absorption, and that is why each capsule delivers 250mg of NMN inside a Liposomal Encapsulation System. That phospholipid shell is designed to protect the NMN through digestion and support delivery to your cells, where it can be converted into NAD+. The 250mg figure is deliberate. It is the dose used in the Washington University human trial and it sits squarely inside the range studied across the published human research, which matters more to us than printing a bigger number on the label. The capsules are vegan, non-GMO, gluten free, made in the USA, and backed by a 97 day money back guarantee, so you have well past the eight to twelve week window the research uses to judge results for yourself.

References

1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141.
   
   

2. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism. 2018;27(3):529-547.
   
   

3. Yoshino J, Baur JA, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27(3):513-528.
   
   

4. McReynolds MR, Chellappa K, Baur JA. Age-related NAD+ decline. Experimental Gerontology. 2020;134:110888.
   
   

5. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
   
   

6. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS ONE. 2012;7(7):e42357.
   
   

7. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127-1139.
   
   

8. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. 2016;24(6):795-806.
   
   

9. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
   
   

10. Yi L, Maier AB, Tao R, et al. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43.
    
    

11. Katayoshi T, Uehata S, Nakashima N, et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Scientific Reports. 2023;13.
    
    

12. Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021;18(1):54.
    
    

13. Nadeeshani H, Li J, Ying T, Zhang B, Lu J. Nicotinamide mononucleotide (NMN) as an anti-aging health product: promises and safety concerns. Journal of Advanced Research. 2022;37:267-278.
    
    

14. Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults: a randomized, double-blind placebo-controlled study. Nutrients. 2022;14(4):755.